ST Xiangxue (300147.SZ): XLS-103 injection has been approved for clinical trials of drugs.

Wisdom Finance APP news, ST Xiangxue (300147.SZ) announced that its subsidiary Xiangxue Life Science and Technology (Guangdong) Co., Ltd. (hereinafter referred to as "Xiangxue Life Science") has received two "Drug Clinical Trial Approval Notices" issued by the National Medical Products Administration (NMPA) (Notice numbers are: 2025LP03514, 2025LP03515). The XLS-103 injection new drug clinical registration application of Xiangxue Life Science has obtained clinical trial approval.